We cofounded and publicly listed...
Bioxyne (BXN:ASX)
In 2020 Breathe International established its life sciences division, Breathe Life Sciences, with the vision of creating a market leader in the manufacture and supply of novel medicines. In May 2023, Breathe Life Sciences acquired Bioxyne Limited, an ASX-listed company, in a reverse takeover bid.
About Breathe International
Breathe Life Sciences
Established Breathe Life Sciences in 2020 as a fully licensed medicinal cannabis, MDMA, and Psilocybin manufacturer operating in Australia, Germany, the UK, and Japan. Breathe Life Sciences went public on the ASX in May 2023 and trades under ticker BXN:ASX.
Doctime Limited
Doctime is a UK healthcare technology venture cofounded by Breathe International in 2020. Doctime serves emerging markets with digital health services and is the market leader in Bangladesh serving >1 million patients.
Giveplease Technology
Breathe International was a founding shareholder of Giveplease Technology Limited, which provided technology solutions to government charitable organisations. The company is a market leader in Singapore and Malaysia.
Real Estate & Technology
Building a property portfolio powered by prop tech (management and letting technology with machine learning tools).
Our Vision
At Breathe International, we aspire to revolutionise life sciences and healthcare. We aspire to build diversified, long term shareholder value. We are committed to innovation and operational excellence.